

SUBJ ECT INDEX TO VOLUME 2

Amphipathic hypothesis.....	66	Carbon nanotubes.....	253
role of <i>O</i> -linked glycopeptides	66	Cationic lipid-based vectors.....	429
Amphiphilic drug carriers.....	443	for gene therapy.....	429
complement activation-related pseudoallergy by....	443	toxicogenomics of	429
role of lipoproteins	443	Cationic lipids	430
Amphiphilic surfactants	443	construction of.....	430
use in pharmacotherapy.....	443	cytogenomics toxicity of	431
Amphotericin B (AmB)	199,177	Chemical penetration enhancers	28,30
effects on human red blood cells (RBC)	180	lipid disruption/fluidisation by.....	28
evaluation of efficacy of.....	202	physical/electrical methods for	31
evaluation of toxicity of.....	201	skin irritancy due to	30
hemolytic activity of.....	180	toxicity due to	30
<i>in vitro</i> drug release studies of.....	179	Chitosan.....	15
<i>in vivo</i> studies of.....	181	chemical structure of.....	15
minimum inhibitory concentration (MIC) of.....	180	general considerations of	15
optimization/preparation of lyophilized MM		<i>in vitro</i> studies of	15
formulations of	178	<i>in vivo</i> studies of.....	17
preparation of.....	200	intestinal enhancing properties of.....	15
preparation of <i>Candida tropicalis</i> inoculate for	201	other derivatives of	17
preparation of red blood cell (RBCs)		physicochemical characteristics of	15
suspension for.....	200	Chitosan-based mucoadhesive microspheres.....	235
Angiogenesis.....	363	as delivery system for antibiotic to stomach.....	235
Angiogenic vasculature.....	363	<i>in vitro</i> drug release studies of.....	236
for EPR-effect.....	367	<i>in vitro</i> mucoadhesion studies of.....	236
liposomal targeting of.....	363	<i>in vitro</i> permeation studies of	238
targeting aminopeptidase N.....	366	<i>in vivo</i> studies in animal model.....	238
targeting cationic liposomes	364	of clarithromycin.....	235
targeting CD105	365	pharmacokinetic analysis of.....	238
targeting MT1-MMP	365	swelling kinetics study of	236
targeting VCAM-1.....	365	Chitosan derivatives	15
Anticoagulants	280	chemical structure of	15
Antigen delivery.....	401	general considerations of	15
lipid-protamine-DNA-mediated.....	401	<i>in vitro</i> studies of	15
Archaeosome immunostimulatory vaccine delivery		<i>in vivo</i> studies of	17
system.....	407	intestinal enhancing properties of.....	15
Archaeosome.....	407	physicochemical characteristics of	15
and archael polar lipids	407	Clarithromycin	236
Blood-brain barrier (BBB).....	59	<i>in vitro</i> drug release studies of.....	236
penetration of.....	59	<i>in vitro</i> mucoadhesion studies of.....	236
peptide drug delivery to brain <i>via</i>	63	<i>in vitro</i> permeation studies of	238
transport mechanisms across	63	<i>in vivo</i> studies in animal model.....	238
use of lipidation in	64	pharmacokinetic analysis of.....	238
use of nanoparticle technology in.....	64	preparation of chitosan microspheres containing ...	236
vectors for penetration <i>via</i>	64	swelling kinetics study of	236
Brain	167	CNS	170
mechanisms involved transnasal transport to	167	delivery of proteins/peptides to.....	170
Brain targeting	165	delivery of non-peptide molecules to.....	170
factors affecting nasal delivery systems of	168	Controlled drug delivery	97
intranasal drug delivery for.....	165	and mathematical modeling	97
through nasal route.....	165	and matrix erosion	107
Cancer tissue.....	354	and matrix swelling equilibrium.....	102
upregulation of secretory phospholipase A2 in.....	354	and matrix swelling kinetics	104
Cancer treatment	369	and non-swelling matrices	101
ligand-mediated targeting for.....	369	role of matrix systems in.....	97
ligand-targeted liposomes for.....	369	Cyclosporine A.....	289
		composition of perfusion solution of.....	290
		determination of.....	291

<i>in-situ</i> mesenteric vein cannulated rat model for....	289	determination of entrapment capacity.....	270
intestinal absorption of	289	evaluation of safety of.....	270
physical characterization of	290	<i>in vivo</i> antibacterial activity of.....	273
preparation of formulations of.....	290	inhibition of bacterial growth by	272
single-pass perfusion method for.....	290	measurements of size distribution of	270
Cytotoxic agent	342	physical characterization of	270
conventional dose of	342	physical stability of	270
fixed dose therapy by.....	343	physicochemical characterization of.....	269
fixed dose <i>vs.</i> body surface area	344	safety to skin cells.....	273
schedule of cytotoxic agents.....	342	susceptibility tests for	270
Cytotoxicity.....	356	use of scanning calorimetry (DSC)	
of proael liposomes activated by sPLA2.....	356	measurements	270
Diclofenac	226	visualization of erythromycin ethosomes	270
anti-inflammatory assay of.....	226	Ethosomes	270
skin irritation assay of	226	preparation of	270
DNA sequencing analysis	216	Expression plasmid	216
Drug delivery	9,320	construction of.....	216
implications for.....	320	Extrusion spheronization.....	1
lipid-core micelles for.....	320	<i>f</i> -CNT	254
loaded with diagnostic agents.....	325	delivery of DNA / ODN CpG with.....	255
micelles for	320	improve immunostimulatory properties of ODN	
micellization for.....	320	CpGs by.....	256
polymeric micelles for	320	presentation of peptide antigens with	257
target for	9	toxicity of.....	254
Drug delivery routes	23	Folate receptors	243
across human skin.....	23	targeting vectors	243
Drugs	353	Folate-linked lipid-based nanoparticle.....	243
in cancer tissue by secretory phospholipase A2	353	for targeted gene delivery.....	243
release of.....	353	Fungizone™ toxicity.....	199
triggered activation of.....	353	induced by use of lipofundin™	199
Drug dissolution.....	105	<i>in vitro</i> study of	199
and diffusion	105	Fungizone™	199
Elastic liposomes	223	Gene therapy	243,423
characterization of	223,224	application of suicide.....	249
determination of amount of drug deposited into		lipid carriers for	423
skin	224	liposomes for.....	244
elasticity measurement of	224	nanoparticles for	244
liposomal formulation of	224	polymers for.....	244
performance evaluation of.....	223	Gene transfection	246
preparation of formulation of	224	activity in various cells	247
preparation of.....	223	folate concentration in	246
skin irritation assay of.....	226	<i>in vitro</i>	246
skin permeation study of.....	224	<i>in vivo</i>	248
Emulsion	309	linker in.....	247
choice of.....	309	Glycopeptide	218
Encapsulated drugs	357	cleavage of.....	218
triggered release of.....	357	deprotection of.....	218
Endogenous opioid peptides	60	Glycopeptide based analgesia	59
sequences of.....	61	prospects for.....	59
stability of	61	Glycopeptide transport.....	71
Endomorphin-1 peptide synthesis.....	218	general method for	71
Enkephalins.....	65	Glycosylation	69
glycosylation of	65	of other opioid peptides	69
Enkephalin structures.....	59	Glycosylation reaction	219
comparison of	59	with carbohydrate-modified endomorphin-1	
Erythromycin ethosomal systems	269	derivatives	219
antibacterial effect of	269,271		

Hemoglobin.....	135	using <i>eligen</i> [®] technology	191
encapsulated vs. unencapsulated type.....	138	Intestinal absorption.....	9
oxygen affinity of	135	effects of chitosans on.....	9
Hemoglobin-based oxygen carriers	133	effects of fatty acids on.....	9
circulation half-life vs. functional half-life of.....	139	effects of medium chain fatty acids (MCFAs) on.....	11
pharmaceutical aspects of.....	133	enhancement <i>via</i> paracellular route	9
toxicity of.....	139	<i>in vitro/in situ</i> studies with sodium caprate for.....	12
viscosity of.....	135	other enhancers for.....	19
Hemoglobin-based oxygen therapeutics	133	Intracellular drug delivery.....	324
current status of	133	lipid-core polymeric micelles.....	324
Heparin.....	277	Intranasal drug delivery.....	168
anticoagulant activity of	278	demerits of	168
coadministration with penetration enhancers	280	merts of	168
gastrointestinal absorption of.....	277	Iron/copper mediated inflammatory disorder.....	261
lipidization of.....	278	pathological roles of metal ions in	262
microparticles for.....	283	treatments for.....	261
pentasaccharides as.....	277	Labetolol hydrochloride (L-HCL).....	125
polymeric delivery systems	282	composition of transdermal drug delivery	
polymeric nanoparticles for.....	283	systems of	126
SNAC / SNAD for.....	283	drug excipient interaction study of	127
use of coadministration with penetration		<i>ex vivo</i> characterization of	125
enhancers.....	277	<i>ex vivo</i> skin permeation studies of	127
use of lipidization	277	<i>in vitro</i> characterization of.....	125
with fatty acids / surfactants	281	<i>in vitro</i> drug release studies of.....	126
with ion-pairing agents	281	<i>in vivo</i> characterization of.....	125
with saponins	282	<i>in vivo</i> pharmacodynamic studies of.....	127
Hypersensitivity	444	stability studies of	127
caused by cremophor EL.....	444	system development of	125
caused by amphiphilic drug carrier systems	444	LgtA	219
caused by poloxamer 188.....	445	expression of.....	219
to poloxamer 188.....	445	purification of.....	219
Immunogens.....	401	Licensed IRIV-based vaccines.....	399
peptides as	401	Ligand-targeted liposomes (LTLs)	369
Immunoliposomes.....	376	cells for	372
clinical evaluation of.....	376	folate receptor in	374
Immunopotentiating reconstituted influenza virosomes	396	internalizing versus non-internalizing antigens by ..	370
cellular immune response of.....	398	principles of	370
composition of.....	396	receptor ligands as targeting moieties in.....	374
functional aspects of.....	397	selection of target receptor.....	370
humoral immune response of	397	selection of target tissues of.....	372
production of.....	396	selection of targeting ligand for	371
structure of.....	396	selection of herapeutic agent for.....	372
Insulin	191	sigma receptor in.....	374
bis-ANS fluorescence of.....	193	therapeutic applications of.....	373
circular dichroism of.....	192	transferrin receptor in.....	374
cytotoxicity measurements of.....	192	Lipid bilayer	423
effect of SNAC on lipophilicity of	194	endosomal escape mechanisms at	424
fluorescently labeled.....	192	Lipid-based nanotechnologies.....	341
immunocytochemistry of.....	192	for anticancer drug combinations	341
mechanistic studies of.....	191	for delivery of fixed dose.....	341
microscopy of.....	192	formulation of	341
oral delivery of.....	191	Lipid-based self-adjuvanting vaccines.....	383
pathway of absorption of	193	Lipid-core micelles.....	319,322
permeability across caco-2 cell monolayers.....	193	and passive tumor targeting	322
permeability measurements of.....	192	for targeted drug delivery	319
protection from enzymatic degradation of.....	194	in circulation	322
proteolysis of	192	Lipid microspheres.....	46
recovery after separation from SNAC.....	194	histopathological examination of.....	48

<i>in vitro</i> release rate studies of.....	46,49	Macrophages	311
<i>in vivo</i> pharmacological evaluation of.....	46,49	in parasitic infections.....	311
morphology of	46	targeted drug delivery to.....	311
plain lipid emulsion (PLE) of	46	Marker molecules.....	12
shape/size/size distribution measurements of.....	49	effects on permeability of	12
structure of	46	Mathematical modeling.....	100
Lipofundin™	199	empirical/semi-empirical approaches to	100
as diluent	199	theoretical approaches to	101
Lipopeptide	385	and non-swelling matrices	101
adjuvants for co-delivery with antigen	387	and matrix swelling equilibrium.....	102
for induction of antibody responses.....	385	and matrix swelling kinetics	104
for induction of T cell responses	386	and matrix erosion	107
mechanism of action of.....	388	Matrices.....	98
Lipoplex	423,431	release mechanism from	99
internalisation of	431	Metastatic tumors.....	405
structure of.....	423	effect of LPD/E7 vaccination on.....	405
targeting of.....	431	Micelles.....	78
transfection pathway of	423	Mononuclear phagocytic system.....	312
Liposomal delivery systems.....	395	antimicrobial activity of	313
as vaccine delivery systems	395	drug homing to	313
characteristics of.....	395	Morphine	59
for vaccines.....	395	comparison of	59
Liposomal drug combinations.....	346	Nanoemulsion particles.....	300
using preclinical models.....	346	materials used to fabricate.....	300
Liposomal prodrugs	353	Nanoemulsions.....	297
in cancer tissue by secretory phospholipase A2.....	353	advantages of	309
release of	353	and dispersions.....	309
triggered activation of	353	and other colloidal preparations.....	309
Liposomes	78,144,345,355	application of	301
analysis of components of	78	assembly of	303
and micromeritics	144	bulk properties of.....	303
drug diffusion studies of.....	144,146	encapsulated phase of	304
drug entrapment studies of	144	engineering of	297
drug leakage studies of	144,146	for drug delivery	297
from prodrug anticancer etherlipids	355	process durability of.....	307
in cancer therapy.....	345	properties of	304
pharmacodynamic studies of	145	science of	297
preparation of.....	144	surface modification at.....	304
preparation of.....	78	technology of	297
response surface analysis of	147	Nano-structured hyperbranched cationic star polymers.....	53
skin permeation studies of.....	145	as high performance gene delivery polymeric	
skin retention studies of.....	145	vectors	53
validation of optimization design of.....	145	cell culture/transfection used for.....	54
vesicle morphology of	144,146	cell viability of	56
Low molecular weight heparin	277	cytotoxicity of.....	54
LPD	403	gene expression of	56
as anti-tumor.....	403	general methods for	54
adjuvant activity of.....	403	polyplex formation for.....	55
Lymphophilized mixed micelle amphotericin B formulation... 177		preparation of.....	55
development of	177	synthesis of	54
effects on human red blood cells (RBC)	180	Naproxen conjugates.....	185
for treatment of systemic fungal infection.....	177	determination of apparent lipophilicity index of ...	187
hemolytic activity of.....	180	determination of chemical solubility of.....	186
<i>in vitro</i> drug release studies of.....	179	determination of chemical stability of	186
<i>in vivo</i> studies of	181	enzymatic hydrolysis of.....	186
minimum inhibitory concentration (MIC) of.....	180	HPLC method for.....	187
		<i>in vitro</i> skin permeation of.....	185
		<i>in vivo</i> analgesic activity of	187

skin permeation experiments of.....	187,188	encapsulation efficiency of prodrug of.....	83
synthesis of.....	185	in liposomal formulations.....	83
synthesis/physico-chemical properties of		<i>in vitro</i> conversion of prodrug into.....	77
prodrugs of.....	187	<i>in vivo</i> conversion of prodrug into.....	77
with -alkylamino acids.....	185	<i>in vivo</i> pharmacokinetic of.....	35
Naproxen.....	185	liposomes of.....	75
determination of chemical solubility of.....	186	local/systemic delivery of.....	35
determination of chemical stability of.....	186	micelles of.....	75
skin permeation experiments of.....	188	pharmacokinetic analysis of.....	37
structure of.....	185	plasma concentration determination of.....	37
Nasal anatomy.....	166	plasma profiles of.....	37
Neurological disorders.....	261	preparation of.....	75
pathological roles of metal ions in.....	262	structure of.....	75
treatments for.....	261	tissue distribution profiles of.....	35,37,39
Nimesulide-loaded liposomal systems.....	143	Paracellular permeability.....	10
and formulation optimization using RSM.....	145	effects of medium chain fatty acids (MCFAs) on.....	11
and micromeritics.....	144	pDNA polyplexes.....	56
anti-inflammatory activity of.....	151	cytotoxicity of.....	56
design of.....	143	Pellets.....	1
development of.....	143	bulk/tapped/granule densities of.....	3
drug diffusion studies of.....	144	density of.....	4
drug entrapment studies of.....	146	dissolution studies of.....	3
drug leakage studies of.....	144	flow properties of.....	3
effect of lipid composition on.....	146	friability of.....	3
experimental design of.....	144	preparation of.....	2
for tropical application.....	143	shape analysis of.....	2,4
optimization of.....	143	size/size distribution analysis of.....	2,3
pharmacodynamic studies of.....	145	Pellet formulations.....	4
response surface analysis of.....	147	density of.....	4
selection of liposomal composition for.....	146	dissolution studies of.....	6
selection of suitable experimental design of.....	146	flow properties of.....	6
skin permeation studies of.....	145	friability testing of.....	6
skin retention studies of.....	145	Pellet properties.....	1
vesicle morphology of.....	144	by extrusion spheronization.....	2
Nose.....	166	influence of excipient variables on.....	1
physiology of.....	166	influence of formulation on.....	1
<i>N</i> -Trimethyl chitosan hydrochloride derivatives (TMC).....	17	Penetration enhancement.....	24
<i>in vitro</i> studies of.....	17	<i>via</i> optimization of drug/vehicle properties.....	24
<i>in vivo</i> studies of.....	17	Peptide-based analgesia.....	61
intestinal enhancing properties of.....	17	Peptide based cancer vaccines.....	401
ODN CpG.....	255	LPD for.....	403
interaction of cationic CNT with.....	255	vaccine adjuvants for.....	402
Opioid.....	60	Permeation enhancers.....	11
receptor subtypes of.....	60	Phospholipid nanosomes encapsulated betulinic acid.....	338
Opioid <i>neo</i> -glycopeptides.....	65	anti-HIV activity of.....	339
Oral heparin.....	278	anti-infective activity of.....	338
development of.....	278	cytotoxicity of.....	339
Oxygen delivery.....	134	Phospholipid nanosomes encapsulated camptothecin.....	337
hemorrhagic shock/principles of.....	134	anticancer activity of.....	338
Paclitaxel.....	35,75	Phospholipid nanosomes encapsulated paclitaxel.....	335
alternative formulations for.....	35	<i>in vitro</i> studies with.....	336
animal treatment with.....	36	<i>in vivo</i> studies with.....	336
as water-soluble prodrug.....	75	stability of.....	335
bioanalysis of.....	37	Phospholipid nanosomes.....	329
biodistribution studies of.....	36	characteristics of.....	333
characterization of.....	75	encapsulated cytochrome-C.....	335
chemical stability of.....	78	manufacturing process of.....	330
		superfluids TM solubility of phospholipids.....	333
		superfluids TM type for.....	332

using supercritical fluids.....	329	shape distribution measurements of.....	49
using superfluid™ CFN equipment.....	320	silymarin lipid emulsion (SLE) in	47
Photo-cation generatable water-soluble polymer.....	209	size/size distribution measurements of	46,49
physical properties of.....	210	Skin penetration retarders	31
preparation of.....	210	Sodium caprate.....	12
synthesis of	209	concentration/time-dependent effects of.....	12
Photo-control.....	207	effects on drug permeability	12
between DNA and photoc-cation generatable		<i>in vivo</i> studies with	14
water-soluble polymers	207	local toxicity of	12
of polyplexes formation	207	mechanism of action of.....	13
Photo-induced polyplex formation	207	Star vectors.....	53
degradation of.....	210	Stratum corneum	28
Plasmid DNA	255	interaction with keratin	29
interaction of cationic CNT with.....	255	increased partitioning by.....	29
Poloxamer drug (pp) micelles	78	solubility in	29
CMC/size measurements of.....	79	mechanisms of	29
differential scanning calorimetry of	79	Synthesis	219
fluorescence anisotropy studies of.....	79	of carbohydrate-modified endomorphin-1	
gel permeation chromatography of.....	79	derivatives	219
preparation of.....	78	Therapeutic chelators	261
release of PM from	79	catalytic RONS deactivators as.....	263
Prodrug (PM)	76,79	classes of	263
chemical stability of.....	78	redox silencers as	265
FT-IR/NMR analysis of.....	77	RONS scavengers as	264
molecular weight determination of.....	77	Topology	98
preparation of.....	76	and matrix structure	98
release studies of.....	78	Transdermal delivery	223
Recombinant DNA techniques	216	animals studies of.....	225
Redox active metal ion.....	261	calculation of permeation parameters of.....	225
mediated rons formation	261	determination of muscle / plasma concentration	
Rofecoxib.....	155	of drug	225
determination of drug content of	157	HPLC assay of	225
for colonic drug delivery	155	of analgesic agent.....	223
guar gum-based matrix tablets of	155	using elastic liposomes	223
HPLC analysis in human plasma.....	157	Transdermal drug delivery system (TDDS).....	125
HPLC analysis of.....	156	drug excipient interaction in	129
immediate release tablets of	157	effect on blood pressure.....	129
<i>in vitro</i> drug release studies of.....	157,158	<i>in vitro</i> drug release from.....	126,128
<i>in vitro</i> evaluation of.....	155	of labetalol hydrochloride.....	125
<i>in vivo</i> evaluation of	155	preparation of.....	125
<i>in vivo</i> studies in healthy human volunteers....	157,161	shelf life of.....	130
pharmacokinetic analysis of	158	skin permeation profile of.....	128
preparation of matrix tablets of	156	stability status of.....	130
Secretory phospholipase A2	354	Transdermal drug delivery	23
as tumour specific liposomal trigger	354	as penetration enhancement technique	23
Silymarin.....	45	effect of chemical potential on.....	26
solution of	47	effects of hydration on	28
Silymarin formulations	45	eutectic systems for.....	26
comparative study of	45	liposomes in	27
estimation of SGOT/SGPT enzyme in	47	penetration enhancement in	28
evaluation by phenobarbitone induced sleep		prodrugs/ion-pairs for	26
time in mice	46	role of saturated/supersaturated solutions in.....	26
histopathological examination of.....	48	solid lipid nanoparticles in.....	28
<i>in vitro</i> release rate studies of	46,49	vesicles in.....	27
<i>in vitro/in vivo</i> evaluation of.....	45	Transfection.....	256,425
<i>in vivo</i> pharmacological evaluation of.....	46,49	development of lipid for enhanced.....	425
plain lipid emulsion (PLE) in	47	with plasmid DNA coated onto <i>f</i> -CNT.....	256
		Trisaccharide-linked peptide	215

chemo-enzymatic synthesis of.....	215	and cationic lipids	93
glycosyltransferase assays of.....	216	and promoters	93
improved drug-delivery by	215	effect on transfection of VSMC/HUAEC/ BHK/293cells.....	94
Tumor angiogenesis	363	effect on transfection	93
targeting of	363	influence of cell types on	93
Unfractionated heparin (UFH).....	277	Virosomes	395
nasal administration of	284	adjuvant of.....	395
Vaccination	404	antigen delivery properties of.....	395
with LPD/E4 nanoparticles	404	interaction with immune system.....	397
Vinblastine	93	Virosome based DNA vaccines	399